Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KiroVax
- Development stage
- Discontinued
- Lead developer
- Kiromic BioPharma
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
KiroVax is an autologous dendritic cell vaccine developed by Kiromic BioPharma for the treatment of various solid malignancies. The therapy involves harvesting a patient's dendritic cells and pulsing them with a proprietary cocktail of tumor-associated poly-antigens (TAPA). These antigens are selected to represent a broad spectrum of targets commonly expressed in solid tumors. Once re-administered to the patient, these primed dendritic cells are intended to activate and expand tumor-specific cytotoxic T lymphocytes (CTLs), thereby mounting an immune response against the cancer. In clinical studies, KiroVax was evaluated in combination with low-dose cyclophosphamide to modulate the tumor microenvironment and topical imiquimod to enhance the immune response.
- Brand names
- KiroVAX
- Other names
- TAPA-pulsed dendritic cell vaccine
02
Targets
PTTG1 (Pituitary tumor-transforming protein 1)
Beyond the preview
Go deeper on KiroVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KiroVax.